Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (Nature, (2020), 586, 7830, (589-593), 10.1038/s41586-020-2639-4)

Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kathleen Neuzil, Vanessa Raabe, Ruth Bailey, Kena A. Swanson, Ping Li, Kenneth Koury, Warren Kalina, David Cooper, Camila Fontes-Garfias, Pei Yong Shi, Özlem Türeci, Kristin R. Tompkins, Edward E. Walsh, Robert FrenckAnn R. Falsey, Philip R. Dormitzer, William C. Gruber, Uğur Şahin, Kathrin U. Jansen

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the print version of this Article, some of the symbols were corrupted in Fig. 4. The HTML and PDF versions of the Article were correct, and so the original Article has not been corrected online.

Original languageEnglish (US)
Pages (from-to)E26
JournalNature
Volume590
Issue number7844
DOIs
StatePublished - Feb 4 2021

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (Nature, (2020), 586, 7830, (589-593), 10.1038/s41586-020-2639-4)'. Together they form a unique fingerprint.

Cite this